Malvern-based Scilex Pharmaceuticals, a subsidiary of Sorrento Therapeutics of San Diego, has received FDA approval for ZTlido, a non-opioid pain medicine, writes John George for the Philadelphia Business Journal.

ZTlido is a transdermal patch treatment for the relief of pain associated with post-herpetic neuralgia, or post-shingles pain. The topical medicine uses proprietary adhesion technology that delivers lidocaine to patients for a 12-hour period.

The approval results in Sorrento paying Scilex $38 million, a balance due from a previous deal.

[uam_ad id=”58459″]

Advertisement

In November 2016, Sorrento acquired a 73 percent ownership stake in Scilex for $47.6 million in stock and cash. The deal was structured so that 80 percent of the purchase price, or $38 million, would not be paid until the drug was approved.

The drug will compete in the pain market with Lidoderm, a product of Endo Pharmaceuticals, which generated $1.6 million in sales last year. Endo has its U.S. headquarters in Malvern.

Read more about Scilex Pharmaceuticals in the Philadelphia Business Journal by clicking here.

[uam_ad id=”72114″]